#Sweden #Stockholm #Sobi #Rare Diseases #Swedish Orphan Biovitrum

Sobi's Annual and Sustainability Report 2024

Swedish Orphan Biovitrum AB, commonly known as Sobi®, has recently released its Annual and Sustainability Report for the year 2024. This significant document outlines the company's progress and future ambitions in transforming the lives of individuals suffering from rare diseases.

Commitment to Sustainability and Innovation

Sobi's dedication to building a sustainable business model is evident throughout the report. The document reveals the company's ongoing efforts to ensure accessibility to approved medicines for individuals within its targeted therapeutic areas. This effort aligns with Sobi's vision of delivering breakthrough innovations that can make a meaningful difference to the lives of patients with rare and debilitating conditions.

Notably, Sobi's report adheres to established guidelines, including the Swedish Annual Accounts Act, and is developed based on the GRI Standards for 2021. These frameworks guide Sobi in maintaining transparency about its sustainability practices and business operations.

Emphasis on Climate and Corporate Responsibility

The report includes crucial information regarding Sobi's alignment with global standards, notably the Task Force on Climate-related Financial Disclosures (TCFD) report and EU Taxonomy disclosures. Sobi is committed to transitioning its efforts to fulfill the Corporate Sustainability Reporting Directive (CSRD), showcasing its proactive approach toward climate-related responsibilities.

Through this report, Sobi aims to meet the stringent requirements set by the new European Sustainability Reporting Standards (ESRS). Adjustments have been made to the report's structure to align with these evolving standards, which reflects Sobi’s commitment to transparency and responsible business practices.

Global Reach and Financial Performance

This year, Sobi generated impressive revenues that reached SEK 26 billion, demonstrating the company's robust performance in the global market. With a dedicated workforce of approximately 1,800 employees spanning across Europe, North America, Asia, Australia, and the Middle East, Sobi's global presence enables it to impact many lives positively through its innovative healthcare solutions.

As a public company listed on Nasdaq Stockholm under the ticker symbol STO SOBI, Sobi continues to forge ahead in the biopharmaceutical sector with a clear aim: to enhance the lives of patients facing rare diseases by ensuring they receive the best medical care possible.

Availability and Accessibility

Sobi’s complete 2024 Annual and Sustainability Report is accessible to the public on the company’s website, sobi.com. The report is also offered in an EU-compliant format, the European Single Electronic Format (ESEF), ensuring that it adheres to regulatory standards for accessibility and readability.

As Sobi continues to innovate and push the boundaries of biopharmaceutical advancements, it remains focused on fostering a sustainable and resilient business that not only prioritizes financial success but also the well-being of its patients and the planet.

This comprehensive look into Sobi's annual activities signifies a commitment not just to profitability, but to a future where innovative medicines are accessible to all who need them, reiterating Sobi's long-standing ethos of putting patients first.